Certara (CERT) AI Stock Analysis

• Market Cap: $1.14B
• Dividend Yield: N/A
• Average Volume (3M): 2.88M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: 11.47%
• EPS Growth: N/A
• Country: US
• Employees: 1,487
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.09
• Shares Outstanding: 159,139,560
• 10 Day Avg. Volume: 3,443,049
• 30 Day Avg. Volume: 2,884,483
• PEG Ratio: 10.22
• Price to Book (P/B): 1.33
• Price to Sales (P/S): 3.37
• P/FCF Ratio: 14.94
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: 2.26
• Enterprise Value/Gross Profit: 3.67
• Enterprise Value/Ebitda: 8.36
• 1Y Price Target: $10.00
• Price Target Upside: 39.86% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): 0.45
• Revenue Forecast (FY): $429.22M

• Rating: 61 Neutral
• Price Target: $7.00 ▼(-2.10% Downside)
• Action: Reiterated Date: 02/26/26
• Date: Action: Reiterated 02/26/26

The score is supported primarily by strong cash generation and a low-risk balance sheet, which reduce downside risk. Offsetting this are weak technical trends, a high P/E valuation, and mixed earnings-call signals including conservative 2026 growth guidance and disclosed execution challenges.

Positive Factors

Conservative balance sheet

Very low leverage materially reduces financial risk and preserves optionality. With minimal debt and a sizable equity base, Certara can fund strategic investments, endure R&D budget cycles, pursue tuck‑ins or divestitures, and maintain revolver availability without pressuring cash flow.

Strong cash generation

Consistent positive operating and free cash flow—even when GAAP earnings were weak—demonstrates durable cash conversion. This supports reinvestment in product and AI, share repurchases, debt service or buffer for restructuring, enhancing resilience during the transition year.

Software growth & high retention

Robust software revenue growth and 107% net retention signal sticky, expanding customer relationships and recurring revenue. Platform-driven demand and MIDD adoption increase predictability and create long-term upsell/cross-sell opportunities that support margin scalability.

Negative Factors

Inconsistent profitability

Volatile earnings and narrow GAAP profitability indicate margin instability. Until adjusted EBITDA gains translate into sustained net income, returns on invested capital may remain constrained and free cash flow could be more exposed to operational setbacks or heavier reinvestment.

Execution & bookings weakness

Quarterly bookings declines and acknowledged execution gaps reduce revenue visibility and lengthen payback on sales investment. Persistent conversion issues among Tier 1/2 customers can slow recurring revenue growth and pressure future margin expansion.

Regulatory-writing business uncertainty

A strategic review introduces structural uncertainty and could lead to divestiture or reorganization. Loss or separation of regulatory-writing capabilities would alter services mix, reduce revenue diversification, and require reallocation of account relationships and go-to-market resources.

Certara Business Overview & Revenue Model

Company Description

Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

How the Company Makes Money

Certara generates revenue primarily through a combination of software licensing fees, professional services, and subscription-based models. Key revenue streams include the sale of its modeling and simulation software products, which are licensed to pharmaceutical companies and research institutions. Additionally, Certara provides consulting services that assist clients with regulatory submissions and drug development strategies, contributing to its earnings. The company also benefits from partnerships with leading pharmaceutical firms and research organizations, which enhance its market reach and credibility. Furthermore, Certara's subscription services for ongoing access to its software and tools create a stable, recurring revenue stream.

Certara Financial Statement Overview

Summary

Strength is driven by a very conservative balance sheet (low debt vs. ~$1.06B equity) and consistently strong operating/free cash flow (FY2025 OCF ~$96M; FCF ~$95M). The main offset is uneven profitability, with losses in 2023–2024 and only near breakeven net results in 2025, indicating margin stability remains a key risk.

Income Statement

Revenue growth has been solid over time (up from $244M in 2020 to $419M in 2025), indicating healthy demand. Profitability, however, has been inconsistent: the company swung from positive earnings in 2022 to sizable losses in 2023–2024, and was near breakeven in 2025 (net loss of ~$1.6M). Operating profit improved meaningfully from 2023’s deep loss to a positive result in 2025, but overall margins and earnings stability remain a key weakness.

Balance Sheet

The balance sheet is a clear strength, with very low debt relative to equity in 2025 (total debt of ~$11M versus equity of ~$1.06B). Earlier years showed moderate leverage (debt-to-equity around ~0.29 in 2021–2024), but the step-down in debt reduces financial risk materially. Total assets have remained stable (~$1.55–$1.58B), and the equity base is large, though returns to shareholders have been pressured in loss-making years.

Cash Flow

Cash generation has been consistently strong: operating cash flow remained positive every year and reached ~$96M in 2025, with free cash flow also high at ~$95M. While free cash flow has declined in recent years (negative growth in 2023–2025), the business still converts well to cash and has maintained substantial free cash flow even when accounting earnings were negative, supporting flexibility for reinvestment and balance-sheet strength.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	418.84M	385.15M	354.34M	335.64M	286.10M
Gross Profit	257.71M	230.63M	213.31M	203.07M	174.49M
EBITDA	83.91M	72.37M	23.84M	89.00M	58.58M
Net Income	-1.59M	-12.05M	-55.36M	14.73M	-13.27M
Balance Sheet
Total Assets	1.56B	1.58B	1.56B	1.57B	1.51B
Cash, Cash Equivalents and Short-Term Investments	189.39M	179.18M	234.95M	236.59M	185.80M
Total Debt	11.40M	311.90M	302.57M	308.13M	308.38M
Total Liabilities	493.79M	516.45M	516.30M	493.26M	469.88M
Stockholders Equity	1.06B	1.06B	1.05B	1.08B	1.04B
Cash Flow
Free Cash Flow	94.56M	78.84M	80.98M	91.11M	51.49M
Operating Cash Flow	96.33M	80.47M	82.75M	92.54M	60.39M
Investing Cash Flow	-26.56M	-112.37M	-79.55M	-27.84M	-269.92M
Financing Cash Flow	-63.99M	-21.01M	-9.45M	-7.36M	123.39M

Certara Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CERT, the sentiment is Negative. The current price of 7.15 is above the 20-day moving average (MA) of 6.88, below the 50-day MA of 8.26, and below the 200-day MA of 10.19, indicating a neutral trend. The MACD of -0.33 indicates Negative momentum. The RSI at 44.18 is Neutral, neither overbought nor oversold. The STOCH value of 85.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CERT.

Certara Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CERT	61 Neutral	$1.14B	-885.94	-0.15%	―	11.47%	―
OMCL	54 Neutral	$1.92B	1,014.72	0.17%	―	10.67%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SDGR	50 Neutral	$961.94M	-12.72	-26.29%	―	32.90%	1.85%
HCAT	50 Neutral	$136.51M	-2.26	-31.33%	―	4.64%	-17.17%
SOPH	48 Neutral	$293.78M	-3.99	-86.09%	―	13.66%	-2.65%
DH	47 Neutral	$174.23M	-2.20	-47.69%	―	-5.30%	46.01%

Certara Corporate Events

Certara Appoints Jon Resnick as New CEO

On December 11, 2025, Certara, a leader in model-informed drug development, announced the appointment of Jon Resnick as the new Chief Executive Officer, effective January 1, 2026. Resnick, who brings over 20 years of experience from IQVIA, will succeed William F. Feehery, who will step down on December 31, 2025, and serve as an advisor during the transition. The company reaffirmed its 2025 financial outlook, indicating stability and confidence in the leadership transition. Resnick’s appointment is expected to propel Certara’s growth and innovation in drug discovery and development, leveraging his extensive experience in healthcare strategy and operations.

The most recent analyst rating on (CERT) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Certara stock, see the CERT Stock Forecast page.